Cristina Tassorelli News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Atogepant superior to rimegepant in reducing monthly migraine days at 12 weeks

Atogepant superior to rimegepant in reducing monthly migraine days at 12 weeks
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Shenaz baghaByrobert herpenCristina tassorelliUniversity of paviaRobert herpen

Atogepant well-tolerated, linked to significant migraine reduction

Atogepant well-tolerated, linked to significant migraine reduction
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesCzech republicUnited kingdomCristina tassorelliByrobert herpenShenaz baghaUniversity of paviaRobert herpen

Teva reveals critical Ajovy data

Teva reveals critical Ajovy data
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

Cristina tassorelliPinar kokturkUniversity of paviaTeva pharmaceutical industriesPharmaceutical industries

Teva s (TEVA) interim analysis of PEARL real-world study on AJOVY reveals sustained long-term effectiveness

Teva s (TEVA) interim analysis of PEARL real-world study on AJOVY reveals sustained long-term effectiveness
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cristina tassorelliPinar kokturkUniversity of paviaHead of medical affairs europe at tevaDepartment of brainBehavioural sciencesTeva pharmaceutical industries ltdEuropean academy of neurologyEuropean headache federationTeva pharmaceutical industriesEuropean academyProfessor cristina tassorelliProfessor tassorelliMedical affairs europePan european real world

Teva s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine

Data presented at the European Academy of Neurology Congress 2023

Pinar kokturkCristina tassorelliBehavioural sciencesUniversity of paviaTeva pharmaceutical industries ltdEuropean headache federationHead of medical affairs europe at tevaInternational headache society clinical trials standing committeeEuropean academy of neurologyDepartment of brainGuidelines of the international headache societyTeva pharmaceutical industriesEuropean academyProfessor cristina tassorelliProfessor tassorelliMedical affairs europe